Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

One Step Quantitative Molecular Approach for Detection of BCR/ABL Translocation and for Monitoring and Follow up of the Minimal Residual Disease in CML Patients Under Tyrosine Kines Inhibitors Treatment

Filomena Daraio, Dr, Davide Barberis, PhD, Francesca Crasto, Dr, Giovanna Rege-Cambrin, Cristina Olivo, PhD, Matteo Renzulli, PhD, Rosy Volpi, PhD, Roberta Lorenzatti, Dr, Carmen Fava, MD, Enrico Gottardi, MD, Giuseppe Saglio, MD

Blood (2012) 120 (21): 4435.

https://doi.org/10.1182/blood.V120.21.4435.4435

Published: 2012

Journal Articles

Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.

Blood (2007) 110 (11): 447.

https://doi.org/10.1182/blood.V110.11.447.447

Published: 2007

Journal Articles

Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).

Michele Cavo, Nicoletta Testoni, Carolina Terragna, Elena Zamagni, Paola Tacchetti, Chiara Nicci, Matteo Renzulli, Elena Montanari, Giulia Perrone, Delia Cangini, Tiziana Grafone, Michela Ceccolini, AnnaMaria Brioli, Giovanni Martinelli, Patrizia Tosi, Michele Baccarani

Blood (2006) 108 (11): 3081.

https://doi.org/10.1182/blood.V108.11.3081.3081

Published: 2006

Journal Articles

CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients.

Matteo Renzulli, C. Terragna, N. Testoni, E. Montanari, P. Tosi, E. Zamagni, P. Tacchetti, G. Perrone, Giovanni Martinelli, M. Baccarani, M. Cavo

Blood (2006) 108 (11): 371.

https://doi.org/10.1182/blood.V108.11.371.371

Published: 2006

Journal Articles

Bone Involvement in Multiple Myeloma Patients Carrying the T (4;14) Chromosomal Translocation.

Patrizia Tosi, MD, Carolina Terragna, PhD, Testoni Nicoletta, PhD, Elena Zamagni, MD, Matteo Renzulli, PhD, Paola Tacchetti, MD, Elena Montanari, MD, Giulia Perrone, MD, Michela Ceccolini, MD, Annamaria Brioli, MD, Michele Baccarani, MD, Michele Cavo, MD

Blood (2006) 108 (11): 4996.

https://doi.org/10.1182/blood.V108.11.4996.4996

Published: 2006

Journal Articles

SU11657, a FLT3-Targeted Tyrosine Kinase, Has Pro-Apoptotic Activity on Leukemia Cells In Vitro.

Tiziana Grafone, Laura Ferraretti, Emanuela Ottaviani, Manuela Mancini, Michela Palmisano, Michele Malagola, Carolina Terragna, Matteo Renzulli, Angela Poerio, Marilina Amabile, Simona Soverini, Sabrina Colarossi, Ilaria Iacobucci, Michele Baccarani, Giovanni Martinelli

Blood (2005) 106 (11): 2797.

https://doi.org/10.1182/blood.V106.11.2797.2797

Published: 2005

Journal Articles

Prognostic Relevance of t(4;14) and Expression of FGFR3 and TACC3 in Newly Diagnosed Patients with Multiple Myeloma.

Carolina Terragna, Matteo Renzulli, Nicoletta Testoni, Chiara Nicci, Tiziana Grafone, Patrizia Tosi, Elena Zamagni, Claudia Cellini, Delia Cangini, Paola Tacchetti, Giulia Perrone, Simona Soverini, Giovanni Martinelli, Michele Baccarani, Michele Cavo

Blood (2005) 106 (11): 5072.

https://doi.org/10.1182/blood.V106.11.5072.5072

Published: 2005

Journal Articles

Gene Expression Profile in the CML Cell Line K562 Treated with SKI-606, a Dual Inhibitor of Src/Abl Kinase.

Matteo Renzulli, Tiziana Grafone, Cristian Taccioli, Carolina Terragna, Frank Boschelli, Manuela Mancini, Pasquale Creo, Emanuela Ottaviani, Sabrina Colarossi, Marilina Amabile, Simona Soverini, Angela Poerio, Ilaria Iacobucci, Michele Baccarani, Giovanni Martinelli

Blood (2005) 106 (11): 4870.

https://doi.org/10.1182/blood.V106.11.4870.4870

Published: 2005

Journal Articles

Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).

Ilaria Iacobucci, Nicoletta Testoni, Gianantonio Rosti, Marilina Amabile, Angela Poerio, Simona Soverini, Sabrina Colarossi, Alessandra Gnani, Emanuela Ottaviani, Fausto Castagnetti, Carolina Terragna, Matteo Renzulli, Tiziana Grafone, Daniela Cilloni, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Giovanni Martinelli

Blood (2005) 106 (11): 1100.

https://doi.org/10.1182/blood.V106.11.1100.1100

Published: 2005

Journal Articles

A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on Chronic Myeloid Leukaemia (CML) Ph+ Cells Resistant to Imatinib.

Giovanni Martinelli, Alberto M. Martelli, Tiziana Grafone, Irina Mantovani, Alessandra Cappellini, Pier Luigi Tazzari, Emanuela Ottaviani, Simona Soverini, Marilina Amabile, Matteo Renzulli, Carolina Terragna, Sabrina Colarossi, Ilaria Iacobucci, Angela Poerio, Michele Baccarani

Blood (2005) 106 (11): 2004.

https://doi.org/10.1182/blood.V106.11.2004.2004

Published: 2005

Journal Articles

A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.

Giovanni Martinelli, Alberto M. Martelli, Tiziana Grafone, Gianantonio Rosti, Irina Mantovani, Alessandra Cappellini, Pier Luigi Tazzari, Emanuela Ottaviani, Matteo Renzulli, Marilina Amabile, Angela Poerio, Simona Soverini, Carolina Terragna, Cristian Taccioli, Simona Bassi, Michele Baccarani

Blood (2004) 104 (11): 4687.

https://doi.org/10.1182/blood.V104.11.4687.4687

Published: 2004

Journal Articles

Down Regulation of TOPK, PBX3, SRPK, DDX21 and CLC Genes in Newly Diagnosed, Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.

Blood (2004) 104 (11): 4650.

https://doi.org/10.1182/blood.V104.11.4650.4650

Published: 2004

Journal Articles

ABL Mutations in Late-Chronic Phase Chronic Myeloid Leukemia Patients with Cytogenetic Refractoriness to Imatinib Are Associated with a Greater Likelihood of Progression to Blast Crisis and Shorter Survival. on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia.

Blood (2004) 104 (11): 1005.

https://doi.org/10.1182/blood.V104.11.1005.1005

Published: 2004

Journal Articles

A Novel 4-anilino-3-quinolinecarbonitrile Dual Src and Abl Kinase Inhibitor (SKI-606) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.

Tiziana Grafone, Manuela Mancini, Emanuela Ottaviani, Matteo Renzulli, Frank Boschelli, Laura Ferraretti, Maria Alessandra Santucci, Marilina Amabile, Simona Soverini, Carolina Terragna, Angela Poerio, Gianantonio Rosti, Cristian Taccioli, Michele Baccarani, Giovanni Martinelli

Blood (2004) 104 (11): 1991.

https://doi.org/10.1182/blood.V104.11.1991.1991

Published: 2004

NARROW

One Step Quantitative Molecular Approach for Detection of BCR/ABL Translocation and for Monitoring and Follow up of the Minimal Residual Disease in CML Patients Under Tyrosine Kines Inhibitors Treatment

Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.

Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).

CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients.

Bone Involvement in Multiple Myeloma Patients Carrying the T (4;14) Chromosomal Translocation.

SU11657, a FLT3-Targeted Tyrosine Kinase, Has Pro-Apoptotic Activity on Leukemia Cells In Vitro.

Prognostic Relevance of t(4;14) and Expression of FGFR3 and TACC3 in Newly Diagnosed Patients with Multiple Myeloma.

Gene Expression Profile in the CML Cell Line K562 Treated with SKI-606, a Dual Inhibitor of Src/Abl Kinase.

Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).

A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on Chronic Myeloid Leukaemia (CML) Ph+ Cells Resistant to Imatinib.

A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.

Down Regulation of TOPK, PBX3, SRPK, DDX21 and CLC Genes in Newly Diagnosed, Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.

ABL Mutations in Late-Chronic Phase Chronic Myeloid Leukemia Patients with Cytogenetic Refractoriness to Imatinib Are Associated with a Greater Likelihood of Progression to Blast Crisis and Shorter Survival. on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia.

A Novel 4-anilino-3-quinolinecarbonitrile Dual Src and Abl Kinase Inhibitor (SKI-606) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only